NASDAQ OMX

VistaJet's US Customer Base Trebles - Reinforcing Its Commanding Position in the Market

Dela

Following strong Q3 results in North America, VistaJet aims to amplify its efforts and resources to continue the positive momentum in the region

 

For North America ending September 30:

  • New Program customers increased three times year over year
  • New Program hours increased 146% year over year
  • Flight departures increased by 30% in Q3 '17 v. Q3 '16
  • Q3 '17 Program hours increased 210% v. Q3 '16
  • 45% of Program customers who have joined in past 12 months have booked additional hours
  • Today's results follow $150 million investment from Rhône Capital

LAS VEGAS, Oct. 09, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, is delighted to announce a set of results that highlights the significant progress made in the US throughout the third quarter ending September 30, 2017. Driving the growth is the company's flagship Program Membership, registering three times more clients year over year, resulting in a 146% increase in Program hours. Moreover, flight hours sold to Program members grew significantly over the period with an increase of 210% compared to Q3 '16. In addition to VistaJet's marked rise in new US passengers, 45% of those who joined as Program customers have gone on to increase the total number of hours flown.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ef21bfc7-9dc9-4c61-a5c1-f7474fef077d

VistaJet's Q3 announcement reinforces the global trend of individuals and corporations moving away from aircraft ownership as they look to shed costs and asset risks, but not the comfort, convenience and benefits of private aviation. Following the $150 million investment from Rhône Capital - which now values VistaJet in excess of $2.5 billion - the company is well positioned to conquer even more fractional and full aircraft owners in the US market, by offering global coverage, consistent unparalleled quality and maximum efficiency.

Thomas Flohr, VistaJet's Founder and Chairman, stated, "We're extremely pleased to announce today's update as it is evidence of the exponential progress VistaJet is making in the US, the core market of private aviation. The numbers we see show two very important things about private aviation in the US. First, there continues to be a trend away from owning aircraft, either entirely or a fraction, given the associated costs and assets risk. Second, demand for high quality private aviation services continues to grow, proven by our ability to treble the number of US Program customers. US customers, both corporate and individual, are discovering that VistaJet is the new generation of business aviation solution. We are leading the industry by building services around the new shared-economy customers, while we keep offering the highest service level, and delivering it in the most efficient manner."

As a result of the company's continued success in the region, VistaJet also announces that it will increase its dedicated US fleet by 50%, to support its growing clients' demand.

To showcase VistaJet's fleet of luxury aircraft, bespoke services and curated details, the company will meet prospective customers in six US cities on board one of its Bombardier Global 5000 aircraft. The tour will allow selected prospective clients to try the VistaJet experience, as have 250,000 passengers already, flying to over 1,600 airports in 187 countries (or 96% of the world). Between October 16-23, a VistaJet Global 5000 will visit Los Angeles, San Francisco, Seattle, Chicago, Boston and New York.

About VistaJet
VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anywhere and at any time.

More VistaJet information and news: www.vistajet.com.
VistaJet Investor information: www.vistajet.com/investors/
VistaJet Direct information: https://www.vistajet.com/direct/

Contact Information:

DKC
Liz Anklow 
Executive Vice President
T: +1.212.981.5103
Liz_Anklow@dkcnews.com

VistaJet
Michael Salamanca
Regional Marketing Manager, The Americas
T: +1.917.755.3734
Michael.Salamanca@vistajet.com

Statements in this release are based solely upon information available as of the date of this release, are not a comprehensive statement of the Company's financial results or positions as of or for the 2017 fiscal year, and have not been audited, reviewed, or compiled by independent registered accounting firm. Therefore, the financial information in this release is preliminary, unaudited and subject to revision upon completion of the Company's closing and audit processes. The company assumes no obligation to update any information contained herein, save for any information required to be disclosed by law.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30Pressmeddelande

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma

Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15Pressmeddelande

BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05Pressmeddelande

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressmeddelande

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29Pressmeddelande

ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum